Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Hemlibra in Mild Hemophilia A

laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of >5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in

  • 0 views
  • 21 Oct, 2021
  • 1 location
Study of TAK-672 in Participants With Acquired Hemophilia A

The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672. Acquired hemophilia A is

  • 0 views
  • 23 Mar, 2022
  • 9 locations
The Hemophilia Inhibitor Prevention Trial

patients with severe hemophilia A.

  • 0 views
  • 21 Oct, 2021
  • 3 locations
The Hemophilia Inhibitor Eradication Trial

inhibitors in severe hemophilia A.

  • 0 views
  • 13 Nov, 2021
  • 2 locations
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will

  • 0 views
  • 14 May, 2022
  • 1 location
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip

The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to FVIII.

  • 0 views
  • 28 Oct, 2021
  • 5 locations
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent

  • 0 views
  • 09 May, 2022
  • 2 locations
HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

hemophilia A patients (baseline FVIII level <40%) with and without inhibitors with hemophilic pseudotumors; secondary outcomes will assess changes in quality of life and activity level in treated patients

  • 0 views
  • 21 Feb, 2022
  • 1 location
A Gene Transfer Study for Hemophilia A

hemophilia A.

antihemophilic factor
cryoprecipitate
  • 842 views
  • 26 Mar, 2022
  • 14 locations
Genetic Background of Patients With Low Von Willebrand Factor Levels (LOVMIC)

Von Willebrand disease (VWD) is caused by either quantitative or qualitative von Willebrand (VWF) defects and is the commonest inherited bleeding disorder with an estimated prevalence of about 1% in the general population. According to several guidelines, patients with a mild quantitative reduction in VWF (30-50 IU/dL) should be labeled …

Accepts healthy volunteers
  • 0 views
  • 08 Mar, 2022